Literature DB >> 16880828

Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.

M S Anscher1, R Clough, C N Robertson, L R Prosnitz, P Dahm, P Walther, C F Donatucci, D M Albala, P Febbo, D J George, L Sun, J W Moul.   

Abstract

To determine the timing and patterns of late recurrence after radical prostatectomy (RP) alone or RP plus adjuvant radiotherapy (RT). Between 1970 and 1983, 159 patients underwent RP for newly diagnosed adenocarcinoma of the prostate and were found to have positive surgical margins, extracapsular extension and/or seminal vesicle invasion. Of these, 46 received adjuvant RT and 113 did not. The RT group generally received 45-50 Gy to the whole pelvis, then a boost to the prostate bed (total dose of 55-65 Gy). In the RP group, 62% received neoadjuvant/adjuvant androgen deprivation vs 17% in the RT group. Patients were analyzed with respect to timing and patterns of failure. Only one patient was lost to follow-up. The median follow-up for surviving patients was nearly 20 years. The median time to failure in the surgery group was 7.5 vs 14.7 years in the RT group (P=0.1). Late recurrences were less common in the surgery group than the RT group (9 and 1% at 10 and 15 years, respectively vs 17 and 9%). In contrast to recurrences, nearly half of deaths from prostate cancer occurred more than 10 years after treatment. Deaths from prostate cancer represented 55% of all deaths in these patients. Recurrences beyond 10 years after RP in this group of patients were relatively uncommon. Despite its long natural history, death from prostate cancer was the most common cause of mortality in this population with locally advanced tumors, reflecting the need for more effective therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880828     DOI: 10.1038/sj.pcan.4500903

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  2 in total

1.  A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.

Authors:  Edouard J Trabulsi; Richard K Valicenti; Alexandra L Hanlon; Thomas M Pisansky; Howard M Sandler; Deborah A Kuban; Charles N Catton; Jeff M Michalski; Michael J Zelefsky; Patrick A Kupelian; Daniel W Lin; Mitchell S Anscher; Kevin M Slawin; Claus G Roehrborn; Jeffrey D Forman; Stanley L Liauw; Larry L Kestin; Theodore L DeWeese; Peter T Scardino; Andrew J Stephenson; Alan Pollack
Journal:  Urology       Date:  2008-07-30       Impact factor: 2.649

2.  A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

Authors:  Roche Kapoor; Matthew P Deek; Riley McIntyre; Natasha Raman; Megan Kummerlowe; Iyah Chen; Matt Gaver; Hao Wang; Sam Denmeade; Tamara Lotan; Channing Paller; Mark Markowski; Michael Carducci; Mario Eisenberger; Tomasz M Beer; Daniel Y Song; Theodore L DeWeese; Jason W Hearn; Stephen Greco; Curtiland DeVille; Neil B Desai; Elisabeth I Heath; Stanley Liauw; Daniel E Spratt; Arthur Y Hung; Emmanuel S Antonarakis; Phuoc T Tran
Journal:  BMC Cancer       Date:  2019-06-13       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.